BDTX-189

Chemical Name:

N-(4-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-7-(2-morpholinoethoxy)quinazolin-6-yl)acrylamide

SMILES Code: 

O=C(NC1=C(C=C(C2=C1)N=CN=C2NC3=CC(Cl)=C(C=C3)OCC4=NC=CC=C4)OCCN5CCOCC5)C=C

InChi Code:

InChI=1S/C29H29ClN6O4/c1-2-28(37)35-25-16-22-24(17-27(25)39-14-11-36-9-12-38-13-10-36)32-19-33-29(22)34-20-6-7-26(23(30)15-20)40-18-21-5-3-4-8-31-21/h2-8,15-17,19H,1,9-14,18H2,(H,35,37)(H,32,33,34)

InChi Key:

HIBPKFXWOPYJPZ-UHFFFAOYSA-N

Keyword:

2414572-47-5;CAS:2414572-47-5;CAS：2414572-47-5;BDTX-189; BDTX 189; BDTX189; EGFR/HER2 inhibitor BDTX-189; ErbB mutant-specific inhibitor BDTX-189

Solubility: Soluble in DMSO

Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years)

Description: 

BDTX-189 is an orally bioavailable, irreversible, selective, small-molecule inhibitor of certain oncogenic driver, allosteric mutations of the ErbB receptor tyrosine kinases epidermal growth factor receptor (EGFR/ErbB1) and human epidermal growth factor receptor 2 (HER2/neu or ErbB2), including extracellular domain allosteric mutations of HER2, and EGFR and HER2 exon 20 insertion mutations, with potential antineoplastic activity. BDTX-189 selectively binds to and inhibits these allosteric ErbB mutants while sparing wild-type EGFR, which may result in the selective inhibition of cellular proliferation and angiogenesis in tumor cells and tumors expressing these allosteric ErbB mutations.

Target: Selective EGFR，HER2 allosteric mutation inhibitors